IgA Nephropathy with Macroproteinuria and a GFR of 20-30 ml/min/1.73 m² May Still Benefit from RAS Inhibition.

ABSTRACT:

Introduction

There has been controversy about renin-angiotensin system (RAS) inhibition in IgAN patients with advanced (stage 4) chronic kidney disease (CKD). Therefore, we investigated the effect of RAS blockade in these patients.

Methods

Renal specimens of 50 IgAN patients who underwent renal biopsy during stage 4 CKD between 2010 and 2020, were stained using immunohistochemistry to detect the expression of RAS receptors (AT1R, AT2R, MasR, and MrgD). The primary endpoint was a composite of end-stage renal disease (ESRD) and death. Main baseline information and the administration of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) were collected.

Results

During a median follow-up time of 25.5 months, 21 (42.0%) patients reached

SUBMITTER: Wang Y 

PROVIDER: S-EPMC9822756 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature